632 related articles for article (PubMed ID: 22829562)
21. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
[TBL] [Abstract][Full Text] [Related]
22. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
23. Polycystic ovaries and obesity.
Messinis IE; Messini CI; Anifandis G; Dafopoulos K
Best Pract Res Clin Obstet Gynaecol; 2015 May; 29(4):479-88. PubMed ID: 25487256
[TBL] [Abstract][Full Text] [Related]
24. Mediators of low-grade chronic inflammation in polycystic ovary syndrome (PCOS).
Ojeda-Ojeda M; Murri M; Insenser M; Escobar-Morreale HF
Curr Pharm Des; 2013; 19(32):5775-91. PubMed ID: 23448487
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
[TBL] [Abstract][Full Text] [Related]
26. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China.
Wang L; Lv S; Li F; Yu X; Bai E; Yang X
Front Endocrinol (Lausanne); 2020; 11():171. PubMed ID: 32296394
[No Abstract] [Full Text] [Related]
27. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
[TBL] [Abstract][Full Text] [Related]
28. Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population.
Aksun S; Sonu NC; Aygun S; Karakulak UN; Mumusoglu S; Yildiz BO
J Endocrinol Invest; 2024 May; 47(5):1129-1137. PubMed ID: 37930586
[TBL] [Abstract][Full Text] [Related]
29. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
30. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
Barber TM; Vojtechova P; Franks S
Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
[TBL] [Abstract][Full Text] [Related]
31. [The metabolic aspects of polycystic ovarian syndrome].
Skałba P; Dabkowska-Huć A
Endokrynol Pol; 2005; 56(6):960-3. PubMed ID: 16821219
[TBL] [Abstract][Full Text] [Related]
32. Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia.
Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Jun; 82(6):1692-6. PubMed ID: 9177365
[TBL] [Abstract][Full Text] [Related]
33. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus.
García-Romero G; Escobar-Morreale HF
Curr Diabetes Rev; 2006 Feb; 2(1):39-49. PubMed ID: 18220616
[TBL] [Abstract][Full Text] [Related]
34. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.
Bril F; Ezeh U; Amiri M; Hatoum S; Pace L; Chen YH; Bertrand F; Gower B; Azziz R
J Clin Endocrinol Metab; 2023 Dec; 109(1):10-24. PubMed ID: 37329216
[TBL] [Abstract][Full Text] [Related]
35. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS.
Zheng SH; Li XL
Gynecol Endocrinol; 2016; 32(3):177-83. PubMed ID: 26502288
[TBL] [Abstract][Full Text] [Related]
36. Cardiometabolic aspects of polycystic ovarian syndrome.
Cho LW; Randeva HS; Atkin SL
Vasc Health Risk Manag; 2007; 3(1):55-63. PubMed ID: 17583175
[TBL] [Abstract][Full Text] [Related]
37. Adipose tissue dysfunction in polycystic ovary syndrome.
Villa J; Pratley RE
Curr Diab Rep; 2011 Jun; 11(3):179-84. PubMed ID: 21424395
[TBL] [Abstract][Full Text] [Related]
38. Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome.
Cree-Green M; Carreau AM; Rahat H; Garcia-Reyes Y; Bergman BC; Pyle L; Nadeau KJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E707-E718. PubMed ID: 30753112
[TBL] [Abstract][Full Text] [Related]
39. Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.
Morrison SA; Goss AM; Azziz R; Raju DA; Gower BA
Hum Reprod; 2017 Jan; 32(1):185-192. PubMed ID: 27827322
[TBL] [Abstract][Full Text] [Related]
40. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
